BRÈVE

sur Cannovation Clinical Research Partners

Cannovation Clinical Research Partners Launches, Aiming to Revolutionize Cannabinoid-Based Therapeutics

Cannovation Clinical Research Partners, a new player in the pharmaceutical and biotech sector, has announced its inauguration in Atlanta, Georgia. The company was founded by Lisa Rich-Milan, a former pharmaceutical executive, and Michael Zaccaria, an experienced leader in the cannabis industry. Cannovation is set to focus on the development and commercialization of cannabinoid-based therapeutics.

The organization has dedicated itself to partnerships across pharmaceutical companies, biotechnology firms, universities, and other Centers of Excellence to push forward the research and development of cannabis-based drugs. Emphasizing a comprehensive approach, Cannovation will support all phases ranging from pre-clinical studies to commercialization in the U.S. market.

Both founders expressed their commitment to bridging the pharmaceutical and cannabis industries through innovation. Rich-Milan highlighted the goal of leveraging cannabinoids to transform medicine, while Zaccaria emphasized on advancing innovation and excellence within their collaborative sectors. Cannovation intends to utilize its broad network to assist clients from product development to launch, ensuring smooth navigations through regulatory frameworks.

R. H.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Cannovation Clinical Research Partners